Texas A&M Health Science Center, School of Medicine, Bryan, TX, 77807, USA.
Houston Methodist Hospital, Dr. Mary and Ron Neal Cancer Center, Houston, TX, 77030, USA.
Ann Hematol. 2024 Jul;103(7):2557-2560. doi: 10.1007/s00277-024-05793-x. Epub 2024 May 15.
Primary cardiac lymphomas (PCLs) are a rare clinical entity, in which treatment guidelines remain to be established. Rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) has been proposed, given that it involves a continuous infusion of anthracycline, reducing the risk of a cardiotoxicity and therefore the theoretical risk of perforation. However, the literature on this method of treatment is scarce. Herein, we present a unique case of a 75-year-old male, diagnosed with primary cardiac diffuse large B-cell lymphoma (DLBCL) with relatively unusual involvement of the coronary sinus, treated first with one cycle of R-EPOCH, followed by three cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) to reduce said risk. To our knowledge, this is one of two cases, in which a patient with PCL was treated this way.
原发性心脏淋巴瘤(PCL)是一种罕见的临床实体,其治疗指南仍有待建立。由于包含连续输注蒽环类药物,因此提出了利妥昔单抗、依托泊苷、泼尼松、长春新碱、环磷酰胺和多柔比星(R-EPOCH)的方案,从而降低了心脏毒性的风险,因此也降低了穿孔的理论风险。然而,关于这种治疗方法的文献很少。在此,我们报告了一例独特的 75 岁男性病例,他被诊断为原发性心脏弥漫性大 B 细胞淋巴瘤(DLBCL),且相对不常见地累及冠状窦,首先接受了一个周期的 R-EPOCH 治疗,然后接受了三个周期的利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松(R-CHOP)治疗,以降低上述风险。据我们所知,这是两例以这种方式治疗 PCL 患者的病例之一。